Multiwell-MEA Segment to Bolster Microelectrode Array in Vitro Market Growth During 2023–2031
According to our new research study on " Microelectrode Array in Vitro Market Forecast to 2031 Global Analysis – by Product and Application" the market is expected to grow from US$ 25.67 million by 2031 from US$ 17.96 million in 2023; it is estimated to grow at a CAGR of 4.6% during 2023–2031. The report highlights trends prevailing in the market, and drivers and restraints pertaining to the market growth.
Multiwell microelectrode arrays are sophisticated experimental platforms comprising a matrix of small electrodes embedded in a substrate, usually organized into multiple wells. The "multiwell" feature of the microelectrode array system refers to its design, which includes multiple distinct wells or chambers similar to those found in standard tissue culture plates. Each well in the array typically contains a biological sample, such as neurons, cardiac cells, or other excitable tissues, and is equipped with multiple electrodes capable of recording electrical signals from these cells or tissues. This design allows researchers to simultaneously investigate different conditions, treatments, or experimental variations. The multiwell format enables high-throughput experiments where multiple conditions or compounds can be tested simultaneously. Their capability to monitor large-scale networks of cells in real time makes them invaluable in fields such as neuroscience, cardiology, toxicology, and stem cell research. This technology helps with the understanding of cellular dynamics, disease mechanisms, and potential therapeutic interventions. A few of the commercially available microelectrode arrays include the Axion Maestro multiwell microelectrode array platform by Axion Biosystems, the MaxTwo High-Density Microelectrode Array System by MaxWell Biosystems, and the Multiwell-MEA System manufactured by Multi Channel Systems MCS GmbH. The Axion Maestro microelectrode array platforms including Maestro Pro Maestro Edge multiwell microelectrode array offers researchers an easy-to-use benchtop assay for analyzing neural and cardiomyocyte network signaling
Rising Focus on Developing Alternatives for Animal Testing Models Is Propelling The Growth of Microelectrode Array in Vitro Market.
Animal models are used widely in biomedical research for human-specific diseases. However, various drug toxicology studies demonstrate that animal models cannot always predict human drug response. This is because there are wide variations in the metabolism of drugs and toxins in humans compared to animals, which makes it nearly impossible to study drug metabolism in experimental models such as laboratory rodent species. Additionally, several regulations have been implemented in recent years, particularly in Europe and North America, that restrict animal use in research activities. Similarly, Cruelty-Free International and the Fund for the Replacement of Animals in Medical Experiments are a few regulatory bodies that oppose animal-based models for research. Such strict regulatory requirements for assessing the toxicity of chemicals, cosmetics, and environmental compounds drive the adoption of microelectrode arrays for in vitro testing. As a result, pharmaceutical and biotechnology companies are encouraged to implement microelectrode array-based testing platforms for screening the neurotoxicity and cardiotoxicity of drugs.
Manufacturers of microelectrode array systems such as BMSEED offer proprietary stretchable microelectrode arrays (sMEAs) and MEASSuRE platform. The use of sMEAs enhances the validity of in vitro experiments by replicating the electrical and mechanical environment of cells, similar to their conditions in vivo, within a controlled setting. By creating a biomimetic environment for cells and tissues, sMEAs can closely mimic the human body, providing more accurate, human-relevant data early in preclinical research. This approach aims to reduce failure rates in human clinical trials.
Thus, the rising focus on developing alternatives for animal models for research fuels the microelectrode array in vitro market growth.
The Microelectrode Array in Vitro Market is segmented on the basis of product, application and geography. The Microelectrode Array in Vitro Market, based on product, is segmented into Classical MEA, Multiwell-MEA and CMOS-MEA. The Multiwell-MEA segment held the largest share of the Microelectrode Array in Vitro Market in 2023, and it is expected to register the highest CAGR during 2023–2031.
Based on application, the market is segmented into Cardiomyocytes, Nerve and Others. Cardiomyocytes are the cells responsible for the contraction and relaxation of the heart. These cells can be derived from human induced pluripotent stem cells that yield high purity. Mature cardiomyocytes have the potential to replace damaged or dysfunctional cardiac tissue and can also be used for screening cardiac drugs and toxins. Using microelectrode arrays, researchers can monitor the electrophysiological responses of cardiomyocytes to different compounds, aiding in the early identification of potential cardiac side effects during drug development. Human pluripotent stem cell-derived cardiomyocytes are an appealing model for researching inherited and drug-induced arrhythmias. These disorders often arise from subtle alterations in electrophysiological properties such as cardiomyocyte excitability, contractility, or both. Microelectrode arrays serve as an important tool for studying the electrophysiological properties of these cells.
The Maestro line of microelectrode arrays offered by Axion Biosystems records functional cell information in cardiac research fields such as cardiotoxicity, stem cell-derived cardiomyocyte development, and excitation-contraction coupling.
In terms of geography, the Microelectrode Array in Vitro Market is segmented into North America (US, Canada, and Mexico), Europe (UK, Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (UAE, Saudi Arabia, Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America). North America held the largest share of the Microelectrode Array in Vitro Market in 2023. Investors are increasingly focusing on companies that produce high-throughput microelectrode arrays for in vitro research, a critical requirement for research institutions, pharmaceutical industries, and the biotechnological sector. Innovations in CMOS-based microelectrode arrays, stem cell research, neuroprosthetics, and in vitro toxicology testing are driving the demand for microelectrode arrays. In June 2020, Georgia State University Research Foundation, Inc. was granted US$ 197.56 million by the US National Science Foundation for their project, which involved the development of microelectrode array sensors for SARS-CoV-2 and other RNA viruses. The project offered a unique opportunity for measurement science to tackle a societal and global crisis through innovative research.
In 2011, the US Environmental Protection Agency highlighted that microelectrode arrays are a valuable system for conducting in vitro toxicity tests, including assessments of developmental neurotoxicity, which presents a significant challenge in the development and approval of new chemicals and drugs. These supportive guidelines by the regulatory bodies in the US have led to the increasing utilization of microelectrode arrays for high-throughput screening in drug discovery and disease modeling as researchers seek reliable platforms for real-time monitoring of cellular and tissue activity.
The growing adoption of microelectrode arrays in vitro models such as organoids has led to the development of innovative technologies, including 3D microelectrode array technology and CMOS-based high-density microelectrode array technology. For instance, in January 2023, BMSEED, a US-based provider of microelectrode array technologies, filed a non-provisional patent application for the advancement of its 2D stretchable microelectrode array (sMEA) into the third dimension, creating the 3D-sMEA. This technology allows electrophysiological measurements from brain organoids and 3D tissue cultures, particularly focused on Alzheimer's disease. The 3D-sMEA features adjustable pockets with embedded electrodes that conform to organoids, enabling researchers to record neural signals from ~80% of the surface area of intact organoids.
Thus, the higher rate of early adoption of emerging microelectrode array technologies and the rising research in the fields of neuroscience, cardiology, and toxicology for creating new therapies for neurological and cardiovascular diseases are likely to increase the demand for microelectrode array in vitro solutions across the US in the near future.
Tucker Davis Technologies; Screen Holdings Co. Ltd.; Plexon, Inc.; Neuronexus; Neuralynx, Inc.; MaxWell Biosystems AG; Harvard Bioscience, Inc.; Blackrock Microsystems LLC; Axion BioSystems, Inc.; and 3Brain AG are among the key players in the market.
Companies operating in the Microelectrode Array in Vitro Market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the Microelectrode Array in Vitro Market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
A few of the developments made by the companies operating in Microelectrode Array in Vitro Market are as follows:
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com